Filana Therapeutics, Inc. Comprehensive Income
Filana Therapeutics, Inc. (FLNA) reported Comprehensive Income of -$2.45 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-07-26.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2018-07-26
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-06-30 was -$2.45M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2018-03-31 was -$2.16M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2017-12-31 was -$2.42M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2017-09-30 was -$2.59M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$11.91M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2016 was -$14.85M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2015 was -$14.15M.
- Filana Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2014 was -$12.39M, a 139.27% decline from fiscal 2013.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$2.45M 10-Q · filed 2018-07-26 | -$4.61M 10-Q · filed 2018-07-26 | -$7.03M derived: sum of 3 quarters · filed 2018-07-26 | -$9.62M derived: sum of 4 quarters · filed 2018-07-26 |
| 2018-03-31 | -$2.16M 10-Q · filed 2018-05-09 | -$4.58M derived: sum of 2 quarters · filed 2018-05-09 | -$7.17M derived: sum of 3 quarters · filed 2018-05-09 | -$11.33M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-12-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-06 | -$5.01M derived: sum of 2 quarters · filed 2018-02-06 | -$9.17M derived: sum of 3 quarters · filed 2018-07-26 | -$11.91M 10-K · filed 2018-02-06 |
| 2017-09-30 | -$2.59M 10-Q · filed 2017-11-01 | -$6.75M derived: sum of 2 quarters · filed 2018-07-26 | -$9.49M 10-Q · filed 2017-11-01 | -$12.02M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-06-30 | -$4.16M 10-Q · filed 2018-07-26 | -$6.90M 10-Q · filed 2018-07-26 | -$9.43M derived: sum of 3 quarters · filed 2018-07-26 | -$12.94M derived: sum of 4 quarters · filed 2018-07-26 |
| 2017-03-31 | -$2.74M 10-Q · filed 2018-05-09 | -$5.27M derived: sum of 2 quarters · filed 2018-05-09 | -$8.78M derived: sum of 3 quarters · filed 2018-05-09 | -$11.80M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | -$2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-06 | -$6.04M derived: sum of 2 quarters · filed 2018-02-06 | -$9.05M derived: sum of 3 quarters · filed 2018-02-06 | -$14.85M 10-K · filed 2018-02-06 |
| 2016-09-30 | -$3.52M 10-Q · filed 2017-11-01 | -$6.53M derived: sum of 2 quarters · filed 2017-11-01 | -$12.33M 10-Q · filed 2017-11-01 | -$16.84M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | -$3.02M 10-Q · filed 2017-08-09 | -$8.81M 10-Q · filed 2017-08-09 | -$13.33M derived: sum of 3 quarters · filed 2017-08-09 | -$17.00M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | -$5.79M 10-Q · filed 2017-04-26 | -$10.31M derived: sum of 2 quarters · filed 2017-04-26 | -$13.98M derived: sum of 3 quarters · filed 2017-04-26 | -$17.36M derived: sum of 4 quarters · filed 2017-04-26 |
| 2015-12-31 | -$4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | -$8.19M derived: sum of 2 quarters · filed 2017-03-07 | -$11.56M derived: sum of 3 quarters · filed 2017-03-07 | -$14.15M 10-K · filed 2017-03-07 |
| 2015-09-30 | -$3.67M 10-Q · filed 2016-10-26 | -$7.04M derived: sum of 2 quarters · filed 2016-10-26 | -$9.63M 10-Q · filed 2016-10-26 | -$11.78M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-06-30 | -$3.37M 10-Q · filed 2016-07-19 | -$5.96M 10-Q · filed 2016-07-19 | -$8.11M derived: sum of 3 quarters · filed 2017-03-07 | -$11.65M derived: sum of 4 quarters · filed 2017-03-07 |
| 2015-03-31 | -$2.58M 10-Q · filed 2016-05-05 | -$4.74M derived: sum of 2 quarters · filed 2017-03-07 | -$8.27M derived: sum of 3 quarters · filed 2017-03-07 | -$11.52M derived: sum of 4 quarters · filed 2017-03-07 |
| 2014-12-31 | -$2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-07 | -$5.69M derived: sum of 2 quarters · filed 2017-03-07 | -$8.94M derived: sum of 3 quarters · filed 2017-03-07 | -$12.39M 10-K · filed 2017-03-07 |
| 2014-09-30 | -$3.53M 10-Q · filed 2015-11-09 | -$6.78M derived: sum of 2 quarters · filed 2015-11-09 | -$10.23M 10-Q · filed 2015-11-09 | $22.78M derived: sum of 4 quarters · filed 2016-03-03 |
| 2014-06-30 | -$3.25M 10-Q · filed 2015-07-23 | -$6.70M 10-Q · filed 2015-07-23 | $26.32M derived: sum of 3 quarters · filed 2016-03-03 | $25.55M derived: sum of 4 quarters · filed 2016-03-03 |
| 2014-03-31 | -$3.45M 10-Q · filed 2015-05-08 | $29.57M derived: sum of 2 quarters · filed 2016-03-03 | $28.80M derived: sum of 3 quarters · filed 2016-03-03 | $28.50M derived: sum of 4 quarters · filed 2016-03-03 |
| 2013-12-31 | $33.02M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $32.25M derived: sum of 2 quarters · filed 2016-03-03 | $31.95M derived: sum of 3 quarters · filed 2016-03-03 | $31.54M 10-K · filed 2016-03-03 |
| 2013-09-30 | -$763.00K 10-Q · filed 2014-11-05 | -$1.06M derived: sum of 2 quarters · filed 2014-11-05 | -$1.47M 10-Q · filed 2014-11-05 | -$3.27M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-06-30 | -$301.00K 10-Q · filed 2014-08-06 | -$706.00K 10-Q · filed 2014-08-06 | -$2.50M derived: sum of 3 quarters · filed 2015-02-18 | -$4.09M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-03-31 | -$411.00K 10-Q · filed 2014-05-07 | -$2.20M derived: sum of 2 quarters · filed 2015-02-18 | -$3.79M derived: sum of 3 quarters · filed 2015-02-18 | -$3.98M derived: sum of 4 quarters · filed 2015-02-18 |
| 2012-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | -$3.38M derived: sum of 2 quarters · filed 2015-02-18 | -$3.57M derived: sum of 3 quarters · filed 2015-02-18 | -$3.57M 10-K · filed 2015-02-18 |
| 2012-09-30 | -$1.59M 10-Q · filed 2013-11-01 | -$1.77M derived: sum of 2 quarters · filed 2013-11-01 | -$1.78M 10-Q · filed 2013-11-01 | -$2.16M derived: sum of 4 quarters · filed 2014-02-05 |
| 2012-06-30 | -$183.00K 10-Q · filed 2013-08-01 | -$186.00K 10-Q · filed 2013-08-01 | -$569.00K derived: sum of 3 quarters · filed 2014-02-05 | -$1.66M derived: sum of 4 quarters · filed 2014-02-05 |
| 2012-03-31 | -$2.00K 10-Q · filed 2013-04-24 | -$386.00K derived: sum of 2 quarters · filed 2014-02-05 | -$1.47M derived: sum of 3 quarters · filed 2014-02-05 | -$2.75M derived: sum of 4 quarters · filed 2014-02-05 |
| 2011-12-31 | -$384.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-05 | -$1.47M derived: sum of 2 quarters · filed 2014-02-05 | -$2.75M derived: sum of 3 quarters · filed 2014-02-05 | -$3.01M 10-K · filed 2014-02-05 |
| 2011-09-30 | -$1.09M 10-Q · filed 2012-11-09 | -$2.36M derived: sum of 2 quarters · filed 2012-11-09 | -$2.63M 10-Q · filed 2012-11-09 | |
| 2011-06-30 | -$1.27M 10-Q · filed 2012-08-02 | -$1.54M 10-Q · filed 2012-08-02 | ||
| 2011-03-31 | -$264.00K 10-Q · filed 2012-05-08 | |||
| 2010-12-31 | -$11.85M 10-K · filed 2013-02-08 | |||
| 2009-12-31 | -$3.44M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |